Massive interest , HUGE VOL. , 100% survival rate > Definitely going higher, especially with a super low float. The company could also announce a 424B5 which would raise cash to help ramp up production/sales. May go well beyond $6.00+
100% survival at 30 days following the use of ultrafiltration in high-risk postoperative coronary artery bypass grafting patients.